Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Asciminib versus investigator-selected TKI in newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase
NL-OMON51998Phase 3Completed
- Sponsor
- Novartis
- Start
- Nov 2022
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of asciminib, imatinib, nilotinib, dasatinib and bosutinib in chronic myelogenous leukemia (CML) (2 arms), sponsored by Novartis. Primary endpoints: Major molecular response at Week 48 and Major molecular response at Week 48 in the imatinib pre-selection stratum. Started Nov 2022; status: completed.
02
Drugs
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on NL-OMON51998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51998.